País: Israel
Idioma: hebreo
Fuente: Ministry of Health
COAGULATION FACTOR VIII RECOMBINANT 250 IU/VIAL
TEVA MEDICAL MARKETING LTD.
B02BD02
POWDER FOR SOLUTION FOR INJECTION
I.V
BAXTER S.A., BELGIUM
COAGULATION FACTOR VIII
The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.
2010-07-01